Meredith McKean, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the DRAGON trial, the first-in-human Phase I trial (NCT04291079) of the latent TGFβ1 inhibitor SRK-181 alone or in combination with anti-PD-L1 treatment in patients with advanced solid tumors. The treatment was well-tolerated, with manageable adverse events. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.